CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Clinical trials for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) explained in plain language.
Never miss a new study
Get alerted when new CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) trials appear
Sign up with your email to follow new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for untreated CLL patients
Disease control CompletedThis study tested a treatment plan for people with previously untreated chronic lymphocytic leukemia (CLL). Participants received up to six cycles of a chemotherapy combination (fludarabine, cyclophosphamide, rituximab) plus lenalidomide, followed by lenalidomide alone as mainten…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: PHASE2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
Double transplant from same donor could reduce lifelong Anti-Rejection drugs
Disease control CompletedThis study tested a combined bone marrow and kidney transplant from a partially matched related donor for 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions and possibly reduce the need for lifelong anti-rejection drugs after th…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New combo therapies show promise for japanese CLL patients
Disease control CompletedThis study tested two drug combinations (venetoclax plus obinutuzumab or ibrutinib) in 20 Japanese adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see how well the treatments worked and how safe they were. P…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New hope for CLL: targeted combo may beat chemo in fit patients
Disease control CompletedThis study tested a combination of two targeted drugs, venetoclax and obinutuzumab, against standard chemotherapy (FCR or BR) in 166 fit patients with previously untreated chronic lymphocytic leukemia (CLL) who lacked certain genetic mutations. The goal was to see if the new comb…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
CAR-T therapy Follow-Up study finds no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various blood cancers like lymphoma and leukemia. The goal was to see if any new or late side effects appeared over time and how long the treatment's effects lasted. It was …
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated May 06, 2026 16:02 UTC